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Abstract:  26 
Context: Polycystic ovary syndrome (PCOS) is a risk factor for dysglycemia, insulin 27 
resistance, and type 2 Diabetes Mellitus (T2DM). Inefficient energy oxidation, metabolic 28 
inflexibility, is a marker of blunted metabolism. We conducted a systematic review on 29 
metabolic inflexibility in women with PCOS. 30 
Evidence Acquisition: We searched MEDLINE, EMBASE and Cochrane central 31 
(inception-October 2018) for studies evaluating metabolic inflexibility and reporting on 32 
changes in Respiratory Quotient (ΔRQ). We extracted data and assessed quality using The 33 
Newcastle-Ottawa Scale.  34 
Evidence Synthesis: We included five prospective cohort studies (461 women). Three 35 
compared PCOS women to unaffected subjects, one to women with obesity or T2DM, and 36 
one to adolescent girls; all had medium quality. Three studies showed higher metabolic 37 
inflexibility in women with PCOS (ΔRQ range 0.05-0.098) compared to unaffected 38 
subjects. Women with PCOS had similar metabolic inflexibility compared to those with 39 
T2DM (ΔRQ 0.05±0.03 vs 0.06±0.04, p=0.98) and obesity (p=0.06). Inflexibility was 40 
higher in hyperandrogenemic women with PCOS (ΔRQ 0.091±0.060 vs 0.120±0.010, 41 
p=0.014). ΔRQ was lower in PCOS women with insulin resistance vs those with normal 42 
insulin sensitivity (0.04±0.02 vs. 0.07±0.04, p=0.007).  43 
 Conclusions: Women with polycystic ovary syndrome appear to have higher metabolic 44 





Introduction  48 
Polycystic ovary syndrome (PCOS) is the commonest endocrine disorder affecting women 49 
of reproductive age with an estimated prevalence between 8–13% 1. It is a known risk 50 
factor for dysglycemia; 75% to 95% of women with PCOS demonstrate insulin resistance, 51 
with a four-fold increased risk for developing gestational and type 2 diabetes mellitus 52 
(T2DM) 2,3.  53 
Impaired glucose metabolism could be attributed to the increased insulin resistance,  54 
inadequate glucose uptake in target tissues, impaired glycogen synthesis and inefficient 55 
switching from lipids to glucose oxidation in affected subjects4. Additionally, the reduced 56 
metabolic capability to switch from lipid oxidation in fasting conditions to lipid 57 
availability in glucose rich conditions, termed metabolic inflexibility, leads to lipids 58 
accumulation in ectopic tissues (e.g skeletal muscles) inducing lipotoxicity with 59 
worsening insulin resistance 5. Thus a vicious cycle of hyperinsulinemia, ectopic fat 60 
storage in peripheral tissues and inefficient metabolism develops 6.  61 
Evidence of metabolic inflexibility is well documented in obese and diabetic subjects 62 
suggesting an association with insulin resistance 5. Hypothesising a common pathway, 63 
women with PCOS might have a disposition for both insulin resistance and metabolic 64 
inflexibility. We conducted a systematic review of the literature to evaluate the available 65 
evidence on metabolic inflexibility in women with PCOS. 66 
 67 
Methods: 68 
We undertook a systematic review using a prospectively registered protocol 69 
(CRD42018116809) and reported in line with the PRISMA guidelines 7. 70 
 71 
Literature search  72 
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We searched major electronic databases (MEDLINE, EMBASE and Cochrane central) for 73 
all primary studies evaluating metabolic inflexibility in women with PCOS from inception 74 
until October 2018. We combined the following Mesh search terms using the Boolean 75 
operators AND/OR to screen for relevant articles (polycystic ovary, polycystic ovaries, 76 
PCO, polycystic ovarian syndrome, ovary, inflexibility, flexibility, metabolic, metabolism, 77 
lipids, carbohydrate, clamp, oxidation) (Appendix 1). We did not employ any search 78 
filters or language restrictions. We manually searched the bibliographies of relevant 79 
articles to identify studies not captured by our electronic search. We contacted the authors 80 
of relevant studies to obtain any missing additional data.  81 
 82 
Study selection and inclusion   83 
Two independent reviews (MR and BW) completed the study selection and inclusion 84 
process in two stages, any discrepancies were resolved in consensus with a third reviewer 85 
(ST). First, we screened titles and abstracts to identify potentially relevant articles; then 86 
we reviewed full copies of relevant articles against our inclusion criteria. We included all 87 
primary studies of any design reporting on the metabolic inflexibility (or flexibility) 88 
between women with and without PCOS using respiratory exchange ratio or respiratory 89 
quotient (RQ) as surrogate markers to evaluate metabolic inflexibility. We excluded 90 
studies on animals, case reports, case series, and studies with no appropriately matched 91 
comparison groups.  92 
 93 
Quality assessment of the included studies  94 
We used the Newcastle-Ottawa Scale (NOS) 8 to assess the quality of the included studies 95 
in duplicate by two reviewers (MR) and (BW). Studies were awarded a maximum of four 96 
stars for selection, two for comparability and three for assessment of outcomes. Those 97 
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which scored four stars for selection, two stars of comparability and three stars for 98 
assessment of outcomes were considered to be of high quality. Scores of one star or less 99 
for selection, comparability or outcome assessment were considered to be of low quality. 100 
Any other score combinations were considered of medium quality.   101 
 102 
Data extraction and analysis 103 
Two reviewers (MR and BW) extracted data in duplicate using a piloted electronic data 104 
extraction tool on the study design, number of included participants, inclusion and 105 
exclusion criteria of each study, protocols of the used euglycemic clamp and calorimetry 106 
studies, journal of publication and year of publication. We extracted data on the reported 107 
outcomes including insulin sensitivity, substrate oxidation (carbohydrate and protein), 108 
levels of testosterone, free testosterone, sex hormone binding globulin, free androgen 109 
index. luteinizing hormone, body mass index, fat mass, and free fat mass. We reported the 110 
findings narratively using natural frequencies and percentages. All analyses were 111 
conducted in Microsoft Excel 2013 (Microsoft Inc, Washington 2013).  112 
 113 
Results  114 
Characteristics of included studies 115 
Our electronic search revealed 17 potentially relevant citations, we removed three 116 
duplicates and assessed 14 articles in full against our inclusion criteria. We included five 117 
prospective cohort studies reporting on 461 women (Figure 1). Two were carried out in 118 
the United States of America, two in Poland and one in Italy. All were published in 119 




All studies were relatively small with a median sample size of 98 (range 42-122). Three 122 
compared women with PCOS to unaffected women with normal weight, one to 123 
overweight or obese women and women with T2DM, and one study compared adolescent 124 
girls with PCOS to unaffected subjects (Table 1). All included women were diagnosed 125 
with PCOS based on the National Institute of Health or Rotterdam criteria 9. All studies 126 
evaluated metabolic inflexibility by calculating the difference between the mean RQ in the 127 
fasting state and the mean RQ in the insulin rich state. Metabolic inflexibility was 128 
diagnosed in the group with a significantly lower mean difference (ΔRQ). All studies 129 
employed a calometric breath analysis to evaluate lipid oxidation and used euglycemic 130 
clamp studies to evaluate carbohydrate oxidation between fasting and insulin rich status 131 
(Table 1).  132 
 133 
Quality of included studies 134 
Overall, the quality of included studies was medium; three studies scored highly for the 135 
selection process, and two were of low quality. The majority of studies (80%, 4/5) had a 136 
medium quality for comparability, primarily due to small sample size with a limited 137 
variation in the comparison cohorts in view of the varied phenotype of PCOS in the 138 
general population. Most studies (60%, 3/5) had an adequate assessment of outcomes and 139 
follow up process. (Figure 2) (Appendix 2). 140 
 141 
Metabolic flexibility  142 
Three of the included studies showed evidence of metabolic inflexibility in women with 143 
PCOS compared to healthy, overweight or obese unaffected women 10,11 (Table 2), or to 144 
healthy adolescents (ΔRQ 0.05 ±0.01 vs 0.095 ±0.009, p=0.004) 12. Hyperandrogenemic 145 
women with PCOS had worse metabolic inflexibility compared to those with normal 146 
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androgen profile (ΔRQ 0.091±0.060 vs 0.120±0.010, p=0.014) 11. Women with PCOS 147 
demonstrated similar metabolic inflexibility to unaffected women with T2DM (ΔRQ 148 
0.05±0.03 vs. 0.06±0.04, p=0.98) 10.  149 
 150 
In contrast, two studies from the same research group suggested no difference in 151 
metabolic flexibility between women with PCOS and healthy adults 13,14. Both studies had 152 
a high risk of bias for cohort selection (Appendix 2). Due to variations in the included 153 
controls and selective outcomes reporting, a quantitative pooling of data was not possible 154 
(Table 2). 155 
 156 
Metabolic and endocrine outcomes 157 
All included studies reported higher insulin resistance in women with PCOS compared to 158 
unaffected subjects 10–12, with similar levels compared to unaffected obese women and 159 
those with T2DM 10,13,14.   160 
  161 
Fasting glucose levels were higher in women with PCOS 10,11, but this was not consistent 162 
across all included cohorts 12,14. There was mixed evidence on the efficiency of glucose 163 
and lipid oxidation in women with PCOS with some studies reporting significantly higher 164 
glucose oxidation before the CLAMP study and reduced lipid oxidation before and during 165 
the CLAMP study 12. A clear conclusion could not be reached, due to variations in 166 
reporting across studies.  167 
 168 
Three studies reported lower levels of sex hormone binding globulin in women with 169 
PCOS compared to matched controls 10–12. This was associated with an increase in both 170 
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total 11,12 and free testosterone 10–12. Similarly, free androgen index was higher in women 171 
with PCOS compared to unaffected lean and obese women 10,14 (Table 2). 172 
 173 
Discussion  174 
The findings of our review support an overall association between PCOS and metabolic 175 
inflexibility, however, this was not consistent in all studies included. Inflexibility was 176 
reported in both adult and adolescent women with PCOS suggesting an association 177 
independent to age. It was more pronounced with high BMI, hyperandrogenemia, and 178 
worsening insulin resistance, signifying an impaired metabolism with worsening features 179 
of PCOS. Insulin resistance and blunted carbohydrates oxidation were common features in 180 
all included women, thus a common pathway of inappropriate energy oxidation, metabolic 181 
inflexibility and response to insulin in women with PCOS is apparent.    182 
 183 
Strengths and limitations  184 
To our knowledge, our review is the first to synthesis evidence on the prospect of 185 
metabolic inflexibility in women with PCOS. We used a prospective protocol following a 186 
standardised methodology and a comprehensive search strategy. We included all studies 187 
reporting on elements of metabolic inflexibility and reported on all relevant outcomes 188 
across included studies. We assessed the quality of in included studies and extracted data 189 
in duplicate. The main limitation of this review was the small number of included studies 190 
and the limited number of women included. PCOS has varied phenotypes and thus, the 191 
population reported on in this review might not fully represent all women with PCOS. 192 
There was variation in the reported outcomes with few studies reporting primary 193 
quantitative endpoints in a standardised manner which limited our ability to pool data 194 




Wider implications  197 
Women presenting with symptoms and signs of PCOS often suffer from delayed diagnosis 198 
and fragmented care 15. The associated metabolic risk factors are seldom discussed or 199 
evaluated at diagnosis, driven by a heterogeneous care provision for women with PCOS 200 
across disciplines. Our findings help to define the metabolic risks associated with a 201 
diagnosis of PCOS, aligned with the known increased insulin resistance, T2DM and 202 
cardiovascular risk factors. The majority of included studies reported worsening metabolic 203 
inflexibility with higher BMI, and hyperandrogenemia, thus, establishing those risk 204 
factors at the time of diagnosis could facilitate a more targeted management plan and 205 
better response to treatment. 206 
 207 
The use of CLAMP studies is cumbersome, expensive and invasive; other measures of 208 
insulin resistance lack accuracy as noted in the recent international evidence based 209 
guideline on PCOS management 15. There is a need to establish more efficient surrogate 210 
markers of metabolic inflexibility for use in everyday clinical practice. Kim et al 12 211 
suggested a clinical model to evaluate metabolic inflexibility based on fasting insulin, 212 
triglycerides, and adiponectin levels which explained 62% of the variance in metabolic 213 
inflexibility in the study participants. Developing predictive models with standardised and 214 
easy to record metabolic predictors could help to determine individual metabolic risk 215 
factors in women newly diagnosed with PCOS 16. Other methods could also be employed 216 
to further evaluate the metabolic inflexibility in women with PCOS such as the measuring 217 
lactate and fat to carbohydrate oxidation in exercise settings 17. More studies are needed to 218 
investigate the metabolic response to high-fat diets in women with PCOS as well as the 219 
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role of glucose disposal rate, adipose tissue lipid storage, and mitochondrial function on 220 
metabolic inflexibility 5. 221 
 222 
Weight loss, lifestyle and exercise interventions were shown to improve the metabolic 223 
inflexibility in individuals with obesity and T2DM 4. Losing 10% of body weight with 224 
lifestyle interventions 18 or 30% with bariatric surgery also improved the metabolic 225 
performance and the associated insulin resistance in obese patients 19. There is a need to 226 
evaluate such interventions in women with PCOS to establish their feasibility and 227 
effectiveness in alleviating the established risk factors associated with this condition. To 228 
date, evidence on the benefit of lifestyle interventions in PCOS is varied and limited to a 229 
specific range of outcomes 20. Adjusting lifestyle interventions to the individualised 230 
metabolic characteristics of women with PCOS could increase their effectiveness and 231 
improve compliance. Combining lifestyle interventions with insulin sensitising drugs such 232 
as metformin or myoinositol could help to reduce the associated insulin resistance, 233 
promote weight loss and stabilise the metabolic status in women with PCOS 21,22.  234 
   235 
Our study summaries current evidence on metabolic inflexibility in women with PCOS. 236 
However, larger cohorts with better adjustment for confounding factors (age, ethnicity, 237 
BMI, baseline diet, and phenotype), more standardised reporting of relevant outcomes are 238 
needed 23.  239 
 240 
Conclusion 241 
Women with polycystic ovary syndrome appear to have higher metabolic inflexibility 242 
compared to unaffected women associated with hyperandrogenemia and insulin resistance. 243 
More research is needed to investigate this metabolic feature among all PCOS phenotypes. 244 
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